nátriumoxibat
Nátriumoxibat is a medication used to treat certain types of muscle weakness, including muscle atrophy and myasthenia gravis. It is a beta-2-adrenergic agonist, a class of medications that work by stimulating the body's natural response to sympathomimetic amines, substances that mimic the effects of the sympathetic nervous system.
June 2015, the U.S. Food and Drug Administration (FDA) approved nátriumoxibat under the trade name Gemtek. Gemtek
Clinical trials have demonstrated the effectiveness of nátriumoxibat in treating EDS and ENSS in patients with
Common side effects reported in clinical trials include tremors, insomnia, and increased anxiety. More serious side
Nátriumoxibat is administered orally, typically twice daily, depending on individual tolerance and clinical response. The recommended
It is available in the United States and other countries with strict controls in place to regulate